ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1249

Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs

Sara Naji Rad1, Paris Pacheco2, Luis Calvo2, Htet Htet Maung2, Wajiha Illyas2 and Prachi Anand3, 1Internal Medicine, Nassau University Medical Center, East meadow, NY, 2Internal Medicine, Nassau University Medical Center, East Meadow, NY, 3Chief of Rheumatology, Nassau University Medical Center, East Meadow, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: immunosuppressants, pregnancy and rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Measures and Measurement of Healthcare Quality Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications as Methotrexate, Mycophenolate Mofetil, Leflunomide and Cyclophosphamide. Contraceptive compliance in this group of patients has been shown to be low. Patients are required to use reliable methods of birth control to prevent undesirable consequences. Our goal was to improve documentation of variables which help physicians to assess contraception compliance in this group of patients and minimize the deviation from standard of care.

Methods: This study had two retrospective arms, pre and post-implementation of immunosuppressive section to rheumatology clinic note. Subjects are females (50 cases in each arm) aged 21-50 y/o on immunosuppressive medications who are sextually active. Females with hysterectomy, tubal ligation and prisoners were excluded. Variables subjected to review included plan to conceive, contraception use, contraception method, gynecology referral. We applied Chi-squared test to analyze the data.

Results: Documentation of four variables mentioned above was compared between two 50-patient groups (pre-intervention vs post-intervention). There was statistically significant improvement in documentation of all four variables following the intervention as follows: plan to conceive (84% vs 36%)(p=0.000001), contraception used (90% vs 54%)(p=0.00006), type of contraception (76% vs 50%)(p=0.007), gynecology referral (84% vs 38%)(p=0.000002).

Conclusion: Identification of variables which represent patients’ compliance is essential and should be addressed in each patient visit. In this study we improved documentation of variables which could help clinician in early recognizing patients who do not follow the guidelines for contraception to consider them for close monitoring or switch to non-teratogenic medications. In this study in light of poor documentation in the first arm we were unable to compare contraception compliance of patients pre and post intervention.


Disclosure: S. Naji Rad, None; P. Pacheco, None; L. Calvo, None; H. H. Maung, None; W. Illyas, None; P. Anand, None.

To cite this abstract in AMA style:

Naji Rad S, Pacheco P, Calvo L, Maung HH, Illyas W, Anand P. Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/contraception-compliance-in-patients-with-rheumatological-diseases-on-disease-modifying-antirheumatic-and-cytotoxic-drugs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contraception-compliance-in-patients-with-rheumatological-diseases-on-disease-modifying-antirheumatic-and-cytotoxic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology